**From:** xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

**Sent:** 27 September 2022 16:02

**To:** Maria Pitan

**Cc:** xxxxxxxxxxxx; David Coombs; Sandra M. Robinson; Emma Gordon

**Subject:** [EXTERNAL]:RE: Initial scrutiny - Tafasitamab ID3795

**Follow Up Flag:** Follow up

**Flag Status:** Completed

CAUTION: This email originated from outside of the organisation. Do not click links or open attachments unless you recognise the sender and know the content is safe.

Hi Maria,

Thank you to responding to our appeal letter. I can confirm we have nothing further to add.

Many thanks,
xxxx

**xxxxxxxxx**

**Policy and Public Affairs Advisor**

Direct line xxxxxxxxxxxxx

[www.lymphoma-action.org.uk](https://urlsand.esvalabs.com/?u=http%3A%2F%2Fwww.lymphoma-action.org.uk%2F&e=9f250c40&h=147c812d&f=y&p=n)

Lymphoma Action, Unit 3, Bell Business Park, Smeaton Close, Aylsebury, Bucks HP19 8JR

Admin line 01296 619400 | Freephone helpline 0808 808 5555

**From:** Maria Pitan <xxxxxxxxxxxxxxx>
**Sent:** 26 September 2022 14:26
**To:** xxxxxxxxxxx <xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx>
**Cc:** xxxxxxxxxxx < xxxxxxxxxxxxxxxxxxxxxxx >; David Coombs < xxxxxxxxxxxxxxxxxxxx >; Sandra M. Robinson <xxxxxxxxxxxxxxxxxxxxx>; Emma Gordon <xxxxxxxxxxxxxxxxxxxxxxxx>
**Subject:** Initial scrutiny - Tafasitamab ID3795

Dear Tara

In response to Lymphoma Action’s appeal letter, please find attached the initial scrutiny letter sent on behalf of the lead non-executive director for appeals.

If you wish to respond to any of the points in the letter, please could you send a response to me by no later than 5pm on 10 October 2022.

Best wishes

**Maria** **Pitan**

Project Manager - Corporate Office

National Institute for Health and Care Excellence

2nd Floor, 2 Redman Place | London E20 1JQ
Tel: xxxxxxxxxxxxxxxxxxx

Web: [http://nice.org.uk](https://emea01.safelinks.protection.outlook.com/?url=http%3A%2F%2Fnice.org.uk%2F&data=02%7C01%7C%7Ce383be34f1bf4cef5f2208d695b590be%7Cbb5fe714bd394aecb717f034c3286d71%7C0%7C0%7C636861004385729732&sdata=%2F7IGtacClJgfa82j6ZXI31sk5VE2vdxle7BzZkpF5zw%3D&reserved=0) Meetings held in public: [https://www.nice.org.uk/Get-Involved/Meetings-in-public](https://emea01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.nice.org.uk%2FGet-Involved%2FMeetings-in-public&data=02%7C01%7C%7Ce383be34f1bf4cef5f2208d695b590be%7Cbb5fe714bd394aecb717f034c3286d71%7C0%7C0%7C636861004385739741&sdata=s47%2FMtnQ02esVi8WVD0eEj7mMJnaVdkvvFxJBwtLiHk%3D&reserved=0)



--
This message has been checked by Libraesva ESG and is believed to be clean.

This message may contain confidential information. If you are not the intended recipient please inform the sender that you have received the message in error before deleting it. Please do not disclose, copy or distribute information in this e-mail or take any action in relation to its contents. To do so is strictly prohibited and may be unlawful. Thank you for your co-operation.

All messages sent by NICE are checked for viruses, but we recommend that you carry out your own checks on any attachment to this message. We cannot accept liability for any loss or damage caused by software viruses.

[http://www.nice.org.uk](https://urlsand.esvalabs.com/?u=http%3A%2F%2Fwww.nice.org.uk&e=9f250c40&h=29b38937&f=y&p=n)

--
This message has been checked by Libraesva ESG and is found to be clean.